Compare ASAN & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASAN | ABCL |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2020 | 2020 |
| Metric | ASAN | ABCL |
|---|---|---|
| Price | $6.84 | $5.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | ★ $12.46 | $8.40 |
| AVG Volume (30 Days) | 5.5M | ★ 7.5M |
| Earning Date | 06-02-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.93 | 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $790,806,000.00 | $75,128,000.00 |
| Revenue This Year | $10.19 | N/A |
| Revenue Next Year | $7.91 | $21.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 9.25 | ★ 160.56 |
| 52 Week Low | $5.38 | $2.75 |
| 52 Week High | $15.71 | $8.44 |
| Indicator | ASAN | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 42.26 |
| Support Level | $6.45 | $5.23 |
| Resistance Level | $6.88 | $6.79 |
| Average True Range (ATR) | 0.50 | 0.59 |
| MACD | -0.03 | -0.24 |
| Stochastic Oscillator | 15.89 | 7.07 |
Asana Inc is the system of action for work, built for the Agentic Enterprise. It provides a comprehensive solution where humans and AI agents can collaborate effectively so that individuals work smarter, teams move faster, and organizations deliver results. Companies use Asana to connect their work to company goals and orchestrate mission-critical workflows like product launches, employee onboarding, resource planning, tracking company-wide strategic initiatives and more. It manages its operations and allocates resources as a single operating and reportable segment. The company generates revenues from subscriptions from paying customers accessing its cloud-based platform.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.